Amgen Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript

Jan 06, 2022 / 06:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. Thank you for joining us at the Goldman Sachs CEO and Scripted Conference 2022. We're pleased to have Bob Bradway, Chairman and CEO of Amgen. Bob, thank you for joining us, and let me turn it over to you for opening remarks.

Robert A. Bradway - Amgen Inc. - Chairman, CEO & President

Okay. Thank you, Salveen. Thanks for having us, and happy New Year to you and all of your guests at the conference. Let me just say a few remarks, Salveen, and then we can jump straight into Q&A. Obviously, we're excited about how things are setting up for us.

We think we're in a position to deliver attractive results for the long term and that we expect will be built off the strong base that we've established now for Repatha, Otezla, our bone health franchise, which, of course, comprises Prolia and EVENITY. So we're excited about how we think those will contribute to long-term growth. And in addition, our biosimilars franchise, we think is really delivering now as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot